BioCentury
ARTICLE | Strategy

Structural guidance for malaria and TB

May 9, 2013 7:00 AM UTC

The Structural Genomics Consortium is spearheading the three-year Structure-guided Drug Discovery Consortium, which aims to bring pharma-quality medicinal chemistry capabilities to targets against malaria and tuberculosis. With a 3-year, $5 million grant from the Bill & Melinda Gates Foundation and another $10 million in supporting funds already available to its members, the drug discovery consortium will focus on projects that put early stage therapeutic assets in the hands of its key product development partners-Medicines for Malaria Venture

and the Global Alliance for TB Drug Development...